Literature DB >> 9803335

Thiopental inhibits migration of human leukocytes through human endothelial cell monolayers in vitro.

R Hofbauer1, D Moser, H Salfinger, M Frass, S Kapiotis.   

Abstract

OBJECTIVES: The interactions between blood and vascular wall cells are essential for the understanding of pathophysiologic processes, e.g. inflammation. The influence of the anesthetic drug thiopental on leukocyte function is well documented. Recently, an inhibitory effect of thiopental on leukocyte chemotaxis in a Boyden chamber assay (i.e. endothelial cells were not included) was demonstrated. In vivo, leukocytes have to interact with endothelial cell monolayers to invade the tissue. The influence of thiopental on a monolayer of endothelial cells has not yet been investigated. The aim of the current study was to investigate the influence of thiopental on the migration of leukocytes through endothelial cell monolayers (ECM).
MATERIAL AND METHODS: Human umbilical vein endothelial cells (HUVEC) were isolated and cultured on microporous membrane filters to achieve a monolayer. Isolated polymorphonuclear leukocytes (PMNL) as well as ECM were preincubated with different concentrations of thiopental. The rate of leukocyte migration against the chemotactic protein formyl-methyl-leucyl-phenylalanine was measured (n = 7). Thiopental was able to reduce the amount of leukocyte migration through ECM significantly.
CONCLUSION: In conclusion, we could show that thiopental is able to reduce the migration of PMNL through ECM significantly.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9803335     DOI: 10.1007/s001340050698

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  17 in total

Review 1.  Endothelial cell interactions with granulocytes: tethering and signaling molecules.

Authors:  G A Zimmerman; S M Prescott; T M McIntyre
Journal:  Immunol Today       Date:  1992-03

Review 2.  Leukocyte adhesion to endothelium in inflammation.

Authors:  L Osborn
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

3.  CD11/CD18-independent transendothelial migration of human polymorphonuclear leukocytes and monocytes: involvement of distinct and unique mechanisms.

Authors:  A C Issekutz; H E Chuluyan; N Lopes
Journal:  J Leukoc Biol       Date:  1995-04       Impact factor: 4.962

4.  Effects of propofol and thiopentone on polymorphonuclear leukocyte functions in vitro.

Authors:  A Skoutelis; P Lianou; E Papageorgiou; K Kokkinis; K Alexopoulos; H Bassaris
Journal:  Acta Anaesthesiol Scand       Date:  1994-11       Impact factor: 2.105

5.  Quantification of leukocyte migration: improvement of a method.

Authors:  G Sunder-Plassmann; R Hofbauer; G Sengoelge; W H Hörl
Journal:  Immunol Invest       Date:  1996 Jan-Mar       Impact factor: 3.657

6.  Thiopentone and propofol, but not methohexitone nor midazolam, inhibit neutrophil oxidative responses to the bacterial peptide FMLP.

Authors:  D Fröhlich; G Rothe; B Schwall; G Schmitz; J Hobbhahn; K Taeger
Journal:  Eur J Anaesthesiol       Date:  1996-11       Impact factor: 4.330

7.  [Intravenous anesthetics and human neutrophil granulocyte motility in vitro].

Authors:  H G Kress; R Segmüller
Journal:  Anaesthesist       Date:  1987-07       Impact factor: 1.041

8.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

9.  In vitro effects of fentanyl, methohexital, and thiopental on brain endothelial permeability.

Authors:  S Fischer; D Renz; W Schaper; G F Karliczek
Journal:  Anesthesiology       Date:  1995-02       Impact factor: 7.892

10.  Anesthetic agents induce human mononuclear leucocytes to release cytokines.

Authors:  F Rossano; R Tufano; G Cipollaro de L'Ero; G Servillo; A Baroni; M A Tufano
Journal:  Immunopharmacol Immunotoxicol       Date:  1992       Impact factor: 2.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.